PMID- 11691500
OWN - NLM
STAT- MEDLINE
DCOM- 20011205
LR  - 20221207
IS  - 0735-1097 (Print)
IS  - 0735-1097 (Linking)
VI  - 38
IP  - 5
DP  - 2001 Nov 1
TI  - Blood thrombogenicity in type 2 diabetes mellitus patients is associated with 
      glycemic control.
PG  - 1307-12
AB  - OBJECTIVES: This study was designed to determine whether blood thrombogenicity is 
      related to chronic glycemic control in type 2 diabetes mellitus (T2DM). 
      BACKGROUND: Type 2 diabetes mellitus is associated with accelerated 
      atherosclerosis and a high rate of arterial thrombotic complications. Whether 
      increased blood thrombogenicity is associated with glycemic control has not been 
      properly tested. METHODS: Forty patients with T2DM with hemoglobin A1c (HbA1c) > 
      or =7.5% were selected. Maintaining their current hypoglycemic therapies, 
      patients were randomized into a conservative (diet modification plus placebo) or 
      intensive (diet modification plus troglitazone) hypoglycemic regimen for three 
      months. Blood thrombogenicity was measured at baseline and after three months 
      with the Badimon ex vivo perfusion chamber and assessed as platelet-thrombus 
      formation. The repeated measurements allowed every patient to be his/her own 
      control. RESULTS: Patients in both groups (48% and 74% of the conservative and 
      intensive groups, respectively) improved glucose control (HbA1c reduction > or 
      =0.5%), showing a significant decrease in blood thrombogenicity. A significant 
      positive correlation was observed between the reduction in thrombus formation and 
      the reduction in HbA1c (r = 0.47, p < 0.01). The reduction in HbA1c achieved by 
      both treatments was comparable. Patients without glycemic improvement showed no 
      change in blood thrombogenicity. Improved glycemic control was the only 
      significant predictor of a decrease in blood thrombogenicity. CONCLUSIONS: In 
      T2DM, there is an association between improved glycemic control and blood 
      thrombogenicity reduction. The effect of glycemic control on the thrombotic 
      complications of T2DM patients deserves further investigation.
FAU - Osende, J I
AU  - Osende JI
AD  - Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener 
      Cardiovascular Institute, New York, New York 10029, USA.
FAU - Badimon, J J
AU  - Badimon JJ
FAU - Fuster, V
AU  - Fuster V
FAU - Herson, P
AU  - Herson P
FAU - Rabito, P
AU  - Rabito P
FAU - Vidhun, R
AU  - Vidhun R
FAU - Zaman, A
AU  - Zaman A
FAU - Rodriguez, O J
AU  - Rodriguez OJ
FAU - Lev, E I
AU  - Lev EI
FAU - Rauch, U
AU  - Rauch U
FAU - Heflt, G
AU  - Heflt G
FAU - Fallon, J T
AU  - Fallon JT
FAU - Crandall, J P
AU  - Crandall JP
LA  - eng
GR  - 5M01RR0071/RR/NCRR NIH HHS/United States
GR  - P50HL54467-SCOR/HL/NHLBI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Chromans)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazoles)
RN  - 0 (Thiazolidinediones)
RN  - I66ZZ0ZN0E (Troglitazone)
SB  - IM
MH  - Analysis of Variance
MH  - Arteriosclerosis/etiology
MH  - Blood Coagulation/*drug effects
MH  - Blood Coagulation Tests
MH  - Chromans/pharmacology/*therapeutic use
MH  - Combined Modality Therapy
MH  - Diabetes Mellitus, Type 2/*complications/metabolism/*prevention & control
MH  - *Diet, Diabetic
MH  - Double-Blind Method
MH  - Female
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Thiazoles/pharmacology/*therapeutic use
MH  - *Thiazolidinediones
MH  - Thrombosis/blood/*etiology
MH  - Troglitazone
EDAT- 2001/11/03 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/03 10:00
PHST- 2001/11/03 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/03 10:00 [entrez]
AID - S0735-1097(01)01555-8 [pii]
AID - 10.1016/s0735-1097(01)01555-8 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2001 Nov 1;38(5):1307-12. doi: 10.1016/s0735-1097(01)01555-8.